nach oben

Zeitschrift für Gerontologie und Geriatrie

Erschienen in:

23.02.2018 | Original contributions

Prevention of ovariectomy-induced osteoporosis in rats

Comparative study of zoledronic acid, parathyroid hormone (1-34) and strontium ranelate

verfasst von: Zhou-Shan Tao, Wan-Shu Zhou, Xing-Jing Wu, Xin Zhang, Lin Wang, Jia-Bing Xie, Zhu-Jun Xu, Guo-Zheng Ding, Min Yang

Erschienen in: Zeitschrift für Gerontologie und Geriatrie | Ausgabe 2/2019

Einloggen, um Zugang zu erhalten

Abstract

Recently, the use of the pharmacological agents strontium ranelate (SR), parathyroid hormone (1-34, PTH) and zoledronic acid (ZA) has come to prominence for the treatment of osteoporosis due to their ability to prevent bone loss in osteoporotic patients. Although much emphasis has been placed on using pharmacological agents for the prevention of disease, much less attention has been placed on which one is more effective. There is still no direct comparative study on these three drugs. The aim of the present study was to investigate the effect of SR, PTH, ZA on preventing ovariectomy-induced osteoporosis in rats. After bilateral ovariectomy the rats randomly received vehicle, SR (500 mg/kg body weight/day, orally), PTH (20 μg/kg/day, subcutaneously) or a single injection of ZA (0.1 mg/kg, i.v.) until death at 12 weeks. The distal femurs were harvested for evaluation of bone metabolism. The rats treated with ZA demonstrated the highest levels of new bone formation as assessed by microcomputed tomography (CT), biomechanical strength, histological analysis and bone metabolism. Furthermore, PTH and SR showed a stronger effect on improving trabecular bone mass at 12 weeks. The results from the present study demonstrate that systemic administration of PTH, SR and ZA could prevent bone loss, while a single dose of ZA has a better effect on preventing ovariectomy-induced osteoporosis than either PTH or SR.

Vorheriger Artikel Sozioökonomische Determinanten der Mortalität hochaltriger Männer in Österreich

Nächster Artikel Möglichkeiten und Grenzen integrierter Tagespflege in Pflegeheimen

Zhu Z, Zheng T, Lee CG, Homer RJ, Elias JA (2002) Tetracycline-controlled transcriptional regulation systems: advances and application in transgenic animal modeling. Semin Cell Dev Biol 2:121–128CrossRef

Riggs BL, Melton L (1995) The worldwide problem of osteoporosis: insights afforded by epidemiology. Bone 17(5):S505–S511CrossRef

Pei L, Tontonoz P (2004) Fat’s loss is bone’s gain. J Clin Invest 113(6):805CrossRefPubMedPubMedCentral

Rodan GA, Martin TJ (2000) Therapeutic approaches to bone diseases. Science 289(5484):1508–1514CrossRefPubMed

Cooper C, Campion G, Melton L III (1992) Hip fractures in the elderly: a world-wide projection. Osteoporos Int 2(6):285–289CrossRefPubMed

Teitelbaum SL (2010) Stem cells and osteoporosis therapy. Cell Stem Cell 7(5):553–554CrossRefPubMed

Burge R, Dawson-Hughes B, Solomon DH, Wong JB, King A, Tosteson A (2007) Incidence and economic burden of osteoporosis-related fractures in the United States, 2005–2025. J Bone Miner Res 22(3):465–475CrossRefPubMed

Komatsu DE, Brune KA, Liu H, Schmidt AL, Han B, Zeng QQ, Yang X, Nunes JS, Lu Y, Geiser AG, Ma YL, Wolos JA, Westmore MS, Sato M (2009) Longitudinal in vivo analysis of the region-specific efficacy of parathyroid hormone in a rat cortical defect model. Endocrinology 150(4):1570–1579. https://doi.org/10.1210/en.2008-0814 CrossRefPubMed

Chalidis B, Tzioupis C, Tsiridis E, Giannoudis PV (2007) Enhancement of fracture healing with parathyroid hormone: preclinical studies and potential clinical applications. Expert Opin Investig Drugs 16(4):441–449. https://doi.org/10.1517/13543784.16.4.441 CrossRefPubMed

10.

Matos MA, Tannuri U, Guarniero R (2010) The effect of zoledronate during bone healing. J Orthop Traumatol 11(1):7–12. https://doi.org/10.1007/s10195-010-0083-1 CrossRefPubMedPubMedCentral

11.

Nagashima M, Sakai A, Uchida S, Tanaka S, Tanaka M, Nakamura T (2005) Bisphosphonate (YM529) delays the repair of cortical bone defect after drill-hole injury by reducing terminal differentiation of osteoblasts in the mouse femur. Bone 36(3):502–511. https://doi.org/10.1016/j.bone.2004.11.013 CrossRefPubMed

12.

Glatt M, Pataki A, Evans GP, Hornby SB, Green JR (2004) Loss of vertebral bone and mechanical strength in estrogen-deficient rats is prevented by long-term administration of zoledronic acid. Osteoporos Int 15(9):707–715CrossRefPubMed

13.

Wise L, Waldman S, Kasra M, Cheung R, Binnington A, Kandel R, White L, Grynpas M (2005) Effect of zoledronate on bone quality in the treatment of aseptic loosening of hip arthroplasty in the dog. Calcif Tissue Int 77(6):367–375CrossRefPubMed

14.

Bonnelye E, Chabadel A, Saltel F, Jurdic P (2008) Dual effect of strontium ranelate: stimulation of osteoblast differentiation and inhibition of osteoclast formation and resorption in vitro. Bone 42(1):129–138. https://doi.org/10.1016/j.bone.2007.08.043 CrossRefPubMed

15.

Marie PJ (2005) Strontium ranelate: a novel mode of action optimizing bone formation and resorption. Osteoporos Int 16(Suppl 1):S7–S10. https://doi.org/10.1007/s00198-004-1753-8 CrossRefPubMed

16.

Chao M, Hua Q, Yingfeng Z, Guang W, Shufeng S, Yuzhen D, Wei W, Haifeng T (2013) Study on the role of zoledronic acid in treatment of postmenopausal osteoporosis women. Pak J Med Sci 29(6):1381–1384PubMedPubMedCentral

17.

Wu J, Cai XH, Qin XX, Liu YX (2017) The effects of sclerostin antibody plus parathyroid hormone (1-34) on bone formation in ovariectomized rats. Z Gerontol Geriatr. https://doi.org/10.1007/s00391-017-1219-1 CrossRefPubMed

18.

Tabatabaei-Malazy O, Salari P, Khashayar P, Larijani B (2017) New horizons in treatment of osteoporosis. Daru 25(1):2. https://doi.org/10.1186/s40199-017-0167-z CrossRefPubMedPubMedCentral

19.

Tao ZS, Tu KK, Huang ZL, Zhou Q, Sun T, Xu HM, Zhou YL, Lv YX, Cui W, Yang L (2015) Combined treatment with parathyroid hormone (1-34) and beta-tricalcium phosphate had an additive effect on local bone formation in a rat defect model. Med Biol Eng Comput. https://doi.org/10.1007/s11517-015-1402-8 CrossRefPubMed

20.

Tao ZS, Qiang Z, Tu KK, Huang ZL, Xu HM, Sun T, Lv YX, Cui W, Yang L (2015) Treatment study of distal femur for parathyroid hormone (1-34) and beta-tricalcium phosphate on bone formation in critical size defects in rats. J Biomater Appl 30(4):484–491. https://doi.org/10.1177/0885328215592854 CrossRefPubMed

21.

Bain SD, Jerome C, Shen V, Dupin-Roger I, Ammann P (2009) Strontium ranelate improves bone strength in ovariectomized rat by positively influencing bone resistance determinants. Osteoporos Int 20(8):1417–1428CrossRefPubMed

22.

Habermann B, Kafchitsas K, Olender G, Augat P, Kurth A (2010) Strontium ranelate enhances callus strength more than PTH 1‑34 in an osteoporotic rat model of fracture healing. Calcif Tissue Int 86(1):82–89CrossRefPubMed

23.

Chen B, Li Y, Yang X, Xu H, Xie D (2013) Zoledronic acid enhances bone-implant osseointegration more than alendronate and strontium ranelate in ovariectomized rats. Osteoporos Int 24(7):2115–2121. https://doi.org/10.1007/s00198-013-2288-7 CrossRefPubMed

24.

Iwamoto J, Seki A, Sato Y, Matsumoto H (2012) Vitamin K(2) improves renal function and increases femoral bone strength in rats with renal insufficiency. Calcif Tissue Int 90(1):50–59CrossRefPubMed

25.

Yano T, Mei Y, Inoue D (2017) Effect of sequential treatment with bisphosphonates after teriparatide in ovariectomized rats: a direct comparison between risedronate and alendronate. Calcif Tissue Int 101(1):102–110. https://doi.org/10.1007/s00223-017-0263-6 CrossRefPubMedPubMedCentral

26.

Hamann C, Rauner M, Höhna Y, Bernhardt R, Mettelsiefen J, Goettsch C, Günther KP, Stolina M, Han CY, Asuncion FJ (2013) Sclerostin antibody treatment improves bone mass, bone strength, and bone defect regeneration in rats with type 2 diabetes mellitus. J Bone Miner Res 28(3):627–638CrossRefPubMed

27.

Li YF, Zhou CC, Li JH, Luo E, Zhu SS, Feng G, Hu J (2012) The effects of combined human parathyroid hormone (1-34) and zoledronic acid treatment on fracture healing in osteoporotic rats. Osteoporos Int 23(4):1463–1474. https://doi.org/10.1007/s00198-011-1751-6 CrossRefPubMed

28.

Nozaka K, Miyakoshi N, Kasukawa Y, Maekawa S, Noguchi H, Shimada Y (2008) Intermittent administration of human parathyroid hormone enhances bone formation and union at the site of cancellous bone osteotomy in normal and ovariectomized rats. Bone 42(1):90–97CrossRefPubMed

29.

Iwaniec UT, Moore K, Rivera MF, Myers SE, Vanegas SM, Wronski TJ (2007) A comparative study of the bone-restorative efficacy of anabolic agents in aged ovariectomized rats. Osteoporos Int 18(3):351–362CrossRefPubMed

30.

Alkhiary YM, Gerstenfeld LC, Krall E, Westmore M, Sato M, Mitlak BH, Einhorn TA (2005) Enhancement of experimental fracture-healing by systemic administration of recombinant human parathyroid hormone (PTH 1‑34). J Bone Joint Surg Am 87(4):731–741PubMed

31.

Kneissel M, Boyde A, Gasser JA (2001) Bone tissue and its mineralization in aged estrogen-depleted rats after long-term intermittent treatment with parathyroid hormone (PTH) analog SDZ PTS 893 or human PTH(1-34). Bone 28(3):237–250CrossRefPubMed

32.

Wronski TJ, Yen CF (1994) Anabolic effects of parathyroid hormone on cortical bone in ovariectomized rats. Bone 15(1):51–58CrossRefPubMed

33.

Gasser JA, Ingold P, Venturiere A, Shen V, Green JR (2008) Long-term protective effects of zoledronic acid on cancellous and cortical bone in the ovariectomized rat. J Bone Miner Res 23(4):544CrossRefPubMed

34.

Little DG, Smith NC, Williams PR, Briody JN, Bilston LE, Smith EJ, Gardiner EM, Cowell CT (2003) Zoledronic acid prevents osteopenia and increases bone strength in a rabbit model of distraction osteogenesis. J Bone Miner Res 18(7):1300CrossRefPubMed

35.

Rogers MJ, Gordon S, Benford HL, Coxon FP, Luckman SP, Monkkonen J, Frith JC (2000) Cellular and molecular mechanisms of action of bisphosphonates. Cancer 88(12 Suppl):2961–2978CrossRefPubMed

36.

Kwak HB, Kim JY, Kim KJ, Choi MK, Kim JJ, Kim KM, Shin YI, Lee MS, Kim HS, Kim JW, Chun CH, Cho HJ, Hong GY, Juhng SK, Yoon KH, Park BH, Bae JM, Han JK, Oh J (2009) Risedronate directly inhibits osteoclast differentiation and inflammatory bone loss. Biol Pharm Bull 32(7):1193–1198CrossRefPubMed

37.

Drake MT, Clarke BL, Khosla S (2008) Bisphosphonates: mechanism of action and role in clinical practice. Mayo Clin Proc 83(9):1032–1045. https://doi.org/10.4065/83.9.1032 CrossRefPubMed

38.

Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley JA, Cosman F, Lakatos P, Leung PC, Man Z (2007) Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 356(18):1809–1822CrossRefPubMed

39.

Reginster JY, Seeman E, Vernejoul MCD, Adami S, Compston J, Phenekos C, Devogelaer JP, Curiel MD, Sawicki A, Goemaere S (2005) Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) study. J Clin Endocrinol Metab 90(5):2816–2822CrossRefPubMed

40.

Saffar JL (2004) The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med 350(5):459–468CrossRef

41.

Chattopadhyay N, Quinn SJ, Kifor O, Ye CP, Brown EM (2007) The calcium-sensing receptor (CaR) is involved in strontium ranelate-induced osteoblast proliferation. Biochem Pharmacol 74(3):438–447. https://doi.org/10.1016/j.bcp.2007.04.020 CrossRefPubMed

42.

Caverzasio J (2008) Strontium ranelate promotes osteoblastic cell replication through at least two different mechanisms. Bone 42(6):1131–1136. https://doi.org/10.1016/j.bone.2008.02.010 CrossRefPubMed

43.

Atkins GJ, Welldon KJ, Halbout P, Findlay DM (2009) Strontium ranelate treatment of human primary osteoblasts promotes an osteocyte-like phenotype while eliciting an osteoprotegerin response. Osteoporos Int 20(4):653–664. https://doi.org/10.1007/s00198-008-0728-6 CrossRefPubMed

44.

Brennan TC, Rybchyn MS, Green W, Atwa S, Conigrave AD, Mason RS (2009) Osteoblasts play key roles in the mechanisms of action of strontium ranelate. Br J Pharmacol 157(7):1291–1300. https://doi.org/10.1111/j.1476-5381.2009.00305.x CrossRefPubMedPubMedCentral

45.

Komrakova M, Hoffmann DB, Nuehnen V, Stueber H, Wassmann M, Wicke M, Tezval M, Stuermer KM, Sehmisch S (2016) The effect of vibration treatments combined with teriparatide or strontium ranelate on bone healing and muscle in ovariectomized rats. Calcif Tissue Int 99(4):1–15CrossRef

Titel: Prevention of ovariectomy-induced osteoporosis in rats
Comparative study of zoledronic acid, parathyroid hormone (1-34) and strontium ranelate
verfasst von: Zhou-Shan Tao
Wan-Shu Zhou
Xing-Jing Wu
Xin Zhang
Lin Wang
Jia-Bing Xie
Zhu-Jun Xu
Guo-Zheng Ding
Min Yang
Publikationsdatum: 23.02.2018
Verlag: Springer Medizin
Erschienen in: Zeitschrift für Gerontologie und Geriatrie / Ausgabe 2/2019
Print ISSN: 0948-6704
Elektronische ISSN: 1435-1269
DOI: https://doi.org/10.1007/s00391-018-1376-x

Springerpflege

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2019

Advance Care Planning: Eine qualitative Untersuchung zur Patientenperspektive bei fortgeschrittener Herzinsuffizienz

Aktuelle Cochrane-Reviews, kommentiert aus geriatrischer Perspektive

Möglichkeiten und Grenzen integrierter Tagespflege in Pflegeheimen

Mitteilungen des BV Geriatrie

Kunsttherapie in der nichtmedikamentösen Therapie chronischer Schmerzen

Validierung des Geriatrie-Checks in einer Kohorte von stationären neurologischen Patienten